Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade

RPT trials demonstrated consistent growth over the past decade, largely driven by robust industry support, and have predominantly focused on targeted ¹⁷⁷Lu-based RPTs for the treatment of prostate adenocarcinoma and gastrointestinal neuroendocrine tumors.